DNA repair and replication proteins as prognostic markers in melanoma

Histopathology

Volumn 62, Issue 2, 2013, Pages 343-350

  Song, Liang ^a   Robson, Tammy ^a   Doig, Tamasin ^b,d   Brenn, Thomas ^b   Mathers, Marie ^b   Brown, Ewan R ^b   Doherty, Val ^c   Bartlett, John M S ^a,e   Anderson, Niall ^a   Melton, David W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c NHS LOTHIAN   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Chemotherapy; ERCC1; Melanomagenesis; Topoisomerase II ; XRCC5

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NUCLEAR PROTEIN; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; XRCC5 PROTEIN;

ADVERSE OUTCOME; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DYSPLASTIC NEVUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MECHANICAL TORSION; MELANOMA; METASTATIC MELANOMA; NEVUS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME;

ANTIGENS, NEOPLASM; DISEASE PROGRESSION; DNA HELICASES; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MALE; MELANOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871142396     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04362.x     Document Type: Article

References (19)

1. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001; 19; 3622-3634.
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009; 27; 6199-6206.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 2004; 351; 998-1012.
4. Li W, Melton DW. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2012; 31; 2412-2422.
5. Song L, Ritchie A-M, McNeil EM, Li W, Melton DW. Identification of DNA repair gene Ercc1 as a novel target in melanoma. Pigment Cell Melanoma Res. 2011; 24; 966-971.
6. Kauffmann A, Rosselli F, Lazar V et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 2008; 27; 565-573.
7. Brown ER, Doig T, Anderson N et al. Association of galectin-3 expression with melanoma progression and prognosis. Eur. J. Cancer 2012; 48; 865-874.
8. Kirkegaard T, Edwards J, Tovey S et al. Observer variation in immunohistochemical analysis of protein expression, time for a change?Histopathology 2006; 48; 787-794.
9. Brase JC, Schmidt M, Fischbach T et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin. Cancer Res. 2010; 16; 2391-2401.
10. Coss A, Tosetto M, Fox EJ et al. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett. 2009; 276; 228-238.
11. Wong N, Yeo W, Wong WL et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int. J. Cancer 2009; 124; 644-652.
12. Kosari F, Munz JM, Savci-Heijink CD et al. Identification of prognostic biomarkers for prostate cancer. Clin. Cancer Res. 2008; 14; 1734-1743.
13. Moeller BJ, Yordy JS, Williams MD et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin. Cancer Res. 2011; 17; 2035-2043.
14. Komuro Y, Watanabe T, Tsurita G, Muto T, Nagawa H. Evaluating the combination of molecular prognostic factors in tumor radiosensitivity in rectal cancer. Hepatogastroenterology 2005; 52; 666-671.
15. Harima Y, Sawada S, Miyazaki Y et al. Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. Am. J. Clin. Oncol. 2003; 26; e80-e85.
16. Saviozzi S, Ceppi P, Novello S et al. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res. 2009; 69; 3390-3396.
17. Skawran B, Steinemann D, Becker T et al. Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Mod. Pathol. 2008; 21; 1479-1789.
18. Lee CF, Ling ZQ, Zhao T et al. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J. Gastroenterol. 2009; 5; 356-365.
19. Jewell R, Conway C, Mitra A et al. Patterns of expression of DNA repair genes and relapse from melanoma. Clin. Cancer Res. 2010; 16; 5211-5221.